Finance

Lists
VTRS:NASDAQ
Viatris Inc
$20.82
+0.73%
(+0.15) 1D
Nov 13, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for VTRS...
Open
$20.77
High
$20.86
Low
$20.38
Mkt. cap
23.87B
Avg. vol.
9.24M
Volume
6.51M
Dividend
2.31%
Quarterly dividend
$0.12
Ex-dividend date
Nov 23, 2026
52-wk high
$21.20
52-wk low
$10.15
EPS
-$0.53
Beta
0.89
Shares outstanding
1.15B
No. of employees
30K
Open
$20.77
High
$20.86
Low
$20.38
Mkt. cap
23.87B
Avg. vol.
9.24M
Volume
6.51M
Dividend
2.31%
Quarterly dividend
$0.12
Ex-dividend date
Nov 23, 2026
52-wk high
$21.20
52-wk low
$10.15
EPS
-$0.53
Beta
0.89
Shares outstanding
1.15B
No. of employees
30K
News stories
From web sources and news partners
Profile
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020. The name of the corporation comes from the Latin words via, meaning path, and tris, which means three, referring to the path to three main objectives the corporation set: expanding access to medicines, meeting patient needs through innovation, and earning the trust of the healthcare community. Viatris ranked 254th on the 2021 Fortune 500 rankings of the largest United States corporations based on its 2020 total revenue. In 2026, Viatris ranked 100 on Time Magazine's World's Most Impactful Companies. Wikipedia
About Viatris Inc
CEOScott A. Smith
Employees30K
FoundedNov 16, 2020
HeadquartersCanonsburg, Pennsylvania, United States
SectorHealth Care
IndustryPharmaceutical industry
Analyst ratings
Based on 9 analysts giving stock ratings to VTRS in the past 3 months
Buy
Buy
5
Hold
3
Sell
1
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for VTRS in the last 3 months.
Highest
Current $20.82
$28.00 (+34.49%)
Average
$21.00 (+0.86%)
Lowest
$14.00 (-32.76%)
Analyst
Recommendation
Action
Price target
Projected
Date
Glen Santangelo
Barclays
Buy
Maintained
$25.00
+20.1%
11/13/2026
Ashwani Verma
UBS
Buy
Reiterated
$28.00
+34.5%
11/09/2026
Chris Schott
J.P. Morgan
Hold
Maintained
$21.00
+0.9%
11/06/2026
David Amsellem
Piper Sandler
Hold
Reiterated
$14.00
-32.8%
10/26/2026
Jason Gerberry
Bank of America Securities
Sell
Maintained
$16.00
-23.2%
10/12/2026
Salveen Richter
Goldman Sachs
Hold
Maintained
$20.00
-3.9%
10/08/2026
Les Sulewski
Oppenheimer
Buy
Initiated
$25.00
+20.1%
09/23/2026
Unknown Analyst
Oppenheimer
Buy
Initiated
$25.00
+20.1%
09/23/2026
Daniel Clark
Leerink Partners
Buy
Initiated
$20.00
-3.9%
09/09/2026
Jasper Hellweg
Argus Research
Buy
Maintained
$20.00
-3.9%
09/08/2026
Unknown Analyst
Jefferies
Buy
Maintained
$17.00
-18.3%
03/20/2026
Last report
Nov 5, 2026
Fiscal period
Q3 2026
$0.71 / $0.64
+11.28%beat
Revenue / Est. (USD)
3.75B / 3.79B
-1.03%miss
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
3.70B
3.52B
3.76B
3.75B
Cost of goods sold
2.21B
2.14B
2.19B
2.14B
Cost of revenue
2.21B
2.14B
2.19B
2.14B
Research and development expenses
271.20M
245.80M
245.20M
229.20M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
933.40M
893.40M
855.00M
861.60M
Operating expense
1.20B
1.14B
1.10B
1.09B
Total operating expenses
3.42B
3.28B
3.29B
3.23B
Operating income
286.00M
238.60M
471.50M
519.40M
Other non operating income
44.90M
-1.80M
14.40M
-13.10M
EBT including unusual items
-343.00M
-247.30M
-64.00M
127.90M
EBT excluding unusual items
185.80M
146.20M
365.40M
413.20M
Income tax expense
-2.90M
-423.70M
54.80M
453.20M
Effective tax rate
0.85%
171.33%
-85.62%
354.34%
Other operating expenses
-
-
-
-
Net income
-340.10M
176.40M
-118.80M
-325.30M
Net profit margin
-9.18%
5.02%
-3.16%
-8.68%
Earnings per share
0.57
0.59
0.69
0.71
Interest and investment income
-
-
-
-
Interest expense
-119.60M
-120.10M
-120.70M
-112.40M
Net interest expenses
-119.60M
-120.10M
-120.70M
-112.40M
Depreciation and amortization charges
-
-
-
-
EBITDA
981.10M
914.70M
1.14B
1.17B
Gain or loss from assets sale
21.90M
13.90M
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps